English
Specials
    Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsContrast media

    Contrast Media

    Jump to
    • Divi’s Lab: Custom synthesis business gaining ground

      Divi’s Lab: Custom synthesis business gaining ground

      With custom synthesis scope widening and fresh opportunities in off-patented API molecules emerging, Divi’s is on a firm footing

    • Weekly Tactical Pick: A pharma stock set to ride emerging opportunities

      Weekly Tactical Pick: A pharma stock set to ride emerging opportunities

      With the emerging threat of the new COVID variant, JN.1, equity markets are likely to be volatile in the coming days. Defensive stocks like Divi’s Lab will merit attention

    • Divi’s Lab: FY25 to witness sizeable improvement in performance

      Divi’s Lab: FY25 to witness sizeable improvement in performance

      The company is enthusiastic about the opportunities in contrast media and peptide building blocks, which shall unfold in 2-5 years

    • Divi’s Lab: Sequential improvement, but long way to go

      Divi’s Lab: Sequential improvement, but long way to go

      An improvement in gross margins is on the cards over the next three to four quarters

    • Divi’s Lab: Green chemistry can set it apart

      Divi’s Lab: Green chemistry can set it apart

      The management of Divi's Lab asserts that there are no Nitrosamine or Azido impurities in the company's Sartan API offerings.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347